Stock Markets Analysis & Opinion

The angst may already be fading away.Last week, I chronicled the carnage across the stocks of home builders that erupted in response to the Republican plan for tax reform that includes a reduction in...

Q3 earnings season is finally starting to wind down, and in nearly every sector of the market, investors have been able to find exciting results. Nevertheless, a few marquee reports remain to be...

As we near the end of the third-quarter earnings season, many investors are ready to look ahead to the fourth quarter and start working out how companies might perform for the full year. Yet there are...

After settling at 2582.75 On Friday’s close, the ES sold off down to 2575.50, down -7.25 handles on Globex Sunday night, but then rallied up to 2584.75, up +2.00 handle before Monday mornings...

Bitcoin is one of the most popular cyrptocurrencies on the market, primarily backed by a rising user base. According to coinmarketcap.com, the market capitalization of the currency presently stands at...

Jazz Pharmaceuticals Public Limited Company (NASDAQ:JAZZ) reported third-quarter 2017 adjusted earnings of $3.22 per share, beating the Zacks Consensus Estimate of $2.89. The bottom line also...

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) reported third-quarter of 2017 results wherein both earnings and sales beat expectations on the back of strong performance of eye-care drug Eylea. ...

Nektar Therapeutics’ (NASDAQ:NKTR) shares increased more than 10% on Nov 7 after reporting better-than-expected third-quarter results with both earnings and sales surpassing...

Agenus Inc. (NASDAQ:AGEN) incurred loss of 37 cents per share in line with the Zacks Consensus Estimate. The figure came in narrower the year-ago loss of 47 cents.Revenues of $3.4 million missed the...

Shares of Keryx Biopharmaceuticals Inc. (NASDAQ:KERX) were down almost 17% on Nov 7 despite receiving FDA approval for a label expansion of its lead drug Auryxia. Lower-than-expected sales of...

Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) incurred a loss of $1.34 per share in the third quarter of 2017, wider than the Zacks Consensus Estimate of a loss of $1.23. The figure was also wider...

Rockwell Automation Inc. (NYSE:ROK) reported adjusted earnings per share of $1.69 in fourth-quarter fiscal 2017 (ended Sep 30, 2017), up 11% from $1.52 recorded in the prior-year quarter. The...

Short term FTSE Elliott Wave view suggests that decline to 7199.5 ended Primary wave ((4)). Up from there, the rally is unfolding as a zigzag Elliott Wave structure where Intermediate wave (A) ended...

With a major chunk of the earnings releases behind us, the quarter seems to have fared quite well so far. While the number of overall positive surprises has been greater than previous periods, the...